BioCentury
ARTICLE | Finance

Building programmable CRISPR platform, Spotlight aims at cancer targets with $36.5M series B

GV-backed, Bay Area biotech focusing on immuno-oncology for internal gene editing pipeline while mulling partnerships elsewhere

March 22, 2022 11:34 AM UTC

With its new $36.5 million series B round, Spotlight is optimizing its platform for programmable, cell-targeted delivery of CRISPR-based gene editing therapies to build an internal pipeline in immuno-oncology, with a broader set of programs ripe for partnering.

Hayward, Calif.-based Spotlight Therapeutics Inc. announced the round Tuesday, with new investors GordonMD Global Investments and EPIQ Capital Group leading a syndicate that also includes series A leader GV...

BCIQ Company Profiles

GV

Spotlight Therapeutics Inc.